Although effective against CIN, warnings for G-CSF therapies include allergic reactions, splenic rupture, acute respiratory distress, alveolar hemorrhage and hemoptysis, with bone pain in 10–30% of patients [5]. The gene discussed is CSF3; the disease is cervical squamous intraepithelial neoplasia.